FASN and breast cancer: Nonetheless, because the PR isoform ratio is a proxy for the molecular signature and endocrine therapy responsiveness of PR+ breast cancer cells, our findings might illuminate new PR-B/FASN-centered predictive and therapeutic modalities in luminal breast cancer intrinsic subtypes.